Michael John Richter, | |
2405 8th St S Ste 200, Moorhead, MN 56560-4200 | |
(218) 331-4866 | |
(218) 331-4867 |
Full Name | Michael John Richter |
---|---|
Gender | Male |
Speciality | Social Worker - Clinical |
Location | 2405 8th St S Ste 200, Moorhead, Minnesota |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124677505 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
1041C0700X | Social Worker - Clinical | 28901 (Minnesota) | Primary |
Entity Name | Nystrom & Associates Ltd |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1396750188 PECOS PAC ID: 6406752492 Enrollment ID: O20031210000592 |
News Archive
Rakesh Pilkar, PhD, research scientist in the Center for Mobility and Rehabilitation Engineering Research at Kessler Foundation, was awarded a $198,102 exploratory research grant by the New Jersey Commission on Spinal Cord Research to conduct a study titled, "A novel system for quasi real-time tracking of neuromuscular responses during electrical stimulation."
In a first-of-its kind controlled experiment, researchers from the Boston University School of Public Health (BUSPH) and Brown University have found that surprisingly, binge drinking the night before a test does not impact college students' test performance - although it can affect their moods, attention and reaction times.
Researchers in the United States have conducted a study suggesting that individuals who have recovered from or been vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) should maintain effective CD8+ T-cell responses against the major variants that have recently emerged.
Individuals with diabetes may have a higher risk of developing mild cognitive impairment, a condition that involves difficulties with thinking and learning and may be an intermediate step toward Alzheimer's disease, according to a report in the April issue of Archives of Neurology, one of the JAMA/Archives journals.
A recent randomized phase III trial conducted by researchers at the Ohio State University, Columbus, OH, US, evaluated the impact of CD24Fc in severe COVID-19 patients and showed promising clinical efficacy. This study is available as a preprint on the medRxiv* server.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Michael John Richter, 2405 8th St S Ste 200, Moorhead, MN 56560-4200 Ph: (218) 331-4866 | Michael John Richter, 2405 8th St S Ste 200, Moorhead, MN 56560-4200 Ph: (218) 331-4866 |
News Archive
Rakesh Pilkar, PhD, research scientist in the Center for Mobility and Rehabilitation Engineering Research at Kessler Foundation, was awarded a $198,102 exploratory research grant by the New Jersey Commission on Spinal Cord Research to conduct a study titled, "A novel system for quasi real-time tracking of neuromuscular responses during electrical stimulation."
In a first-of-its kind controlled experiment, researchers from the Boston University School of Public Health (BUSPH) and Brown University have found that surprisingly, binge drinking the night before a test does not impact college students' test performance - although it can affect their moods, attention and reaction times.
Researchers in the United States have conducted a study suggesting that individuals who have recovered from or been vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) should maintain effective CD8+ T-cell responses against the major variants that have recently emerged.
Individuals with diabetes may have a higher risk of developing mild cognitive impairment, a condition that involves difficulties with thinking and learning and may be an intermediate step toward Alzheimer's disease, according to a report in the April issue of Archives of Neurology, one of the JAMA/Archives journals.
A recent randomized phase III trial conducted by researchers at the Ohio State University, Columbus, OH, US, evaluated the impact of CD24Fc in severe COVID-19 patients and showed promising clinical efficacy. This study is available as a preprint on the medRxiv* server.
› Verified 8 days ago